Trelegy — Milestone payable
Royalty Pharma Trelegy — Milestone payable remained flat by 0.0% to $12.50M in Q4 2025 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $12.50M to $12.50M. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase indicates the achievement of a significant development or commercial milestone, signaling progress in the asset's lifecycle but requiring immediate cash outflow. A decrease suggests a period of stability or the completion of milestone-based obligations.
Detailed definition
This metric represents the contractual obligation to make one-time payments triggered by the achievement of specific reg...
Peer comparison
Similar to contingent consideration or milestone payment obligations found in biopharmaceutical licensing agreements and M&A earn-outs across the life sciences sector.
rprx_segment_trelegy_milestone_payableHistorical Data
| FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|
| Value | $0.00 | $0.00 | $50.00M | $50.00M |
| YoY Change | — | — | — | +0.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's trelegy — milestone payable?
- Royalty Pharma (RPRX) reported trelegy — milestone payable of $12.50M in Q4 2025.
- How has Royalty Pharma's trelegy — milestone payable changed year-over-year?
- Royalty Pharma's trelegy — milestone payable decreased by 0.0% year-over-year, from $12.50M to $12.50M.
- What does trelegy — milestone payable mean?
- The amount of one-time payments due upon reaching specific development or commercial goals for a pharmaceutical product.